{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:59:55Z","timestamp":1787673595542,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H02775"],"award-info":[{"award-number":["JP21H02775"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15314"],"award-info":[{"award-number":["23K15314"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA259188"],"award-info":[{"award-number":["R01 CA259188"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA251674"],"award-info":[{"award-number":["R01 CA251674"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-23-722314"],"award-info":[{"award-number":["RSG-23-722314"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41375-024-02441-1","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T05:02:48Z","timestamp":1729486968000},"page":"243-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-5664","authenticated-orcid":false,"given":"Keito","family":"Suto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-6091","authenticated-orcid":false,"given":"Masahiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9948-8696","authenticated-orcid":false,"given":"Yibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-6054","authenticated-orcid":false,"given":"Masao","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2441_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288\u201398.","journal-title":"Ann Oncol"},{"key":"2441_CR2","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095\u2013100.","journal-title":"Blood"},{"key":"2441_CR3","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"},{"key":"2441_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376\u201384.","journal-title":"Mol Cancer Ther"},{"key":"2441_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2022015646","volume":"140","author":"M Chiba","year":"2022","unstructured":"Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood. 2022;140:1951\u201363.","journal-title":"Blood"},{"key":"2441_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2021012734","volume":"139","author":"T Ishio","year":"2022","unstructured":"Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia\/lymphoma. Blood. 2022;139:1541\u201356.","journal-title":"Blood"},{"key":"2441_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, et al. Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma. Cancer Cell. 2018;34:286\u201397.","journal-title":"Cancer Cell"},{"key":"2441_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41418-018-0192-6","volume":"26","author":"A Fauster","year":"2019","unstructured":"Fauster A, Rebsamen M, Willmann KL, Cesar-Razquin A, Girardi E, Bigenzahn JW, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138\u201355.","journal-title":"Cell Death Differ"},{"key":"2441_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1006\/smim.1998.0156","volume":"10","author":"R Horie","year":"1998","unstructured":"Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10:457\u201370.","journal-title":"Semin Immunol"},{"key":"2441_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4049\/jimmunol.141.2.672","volume":"141","author":"JF Nawrocki","year":"1988","unstructured":"Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin\u2019s disease-related membrane protein. J Immunol. 1988;141:672\u201380.","journal-title":"J Immunol"},{"key":"2441_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41580-023-00593-z","volume":"24","author":"AD McAinsh","year":"2023","unstructured":"McAinsh AD, Kops G. Principles and dynamics of spindle assembly checkpoint signalling. Nat Rev Mol Cell Biol. 2023;24:543\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2441_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ccr.2010.08.010","volume":"18","author":"X Zeng","year":"2010","unstructured":"Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010;18:382\u201395.","journal-title":"Cancer Cell"},{"key":"2441_CR13","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1038\/s41388-020-1187-6","volume":"39","author":"TM Lok","year":"2020","unstructured":"Lok TM, Wang Y, Xu WK, Xie S, Ma HT, Poon RYC. Mitotic slippage is determined by p31(comet) and the weakening of the spindle-assembly checkpoint. Oncogene. 2020;39:2819\u201334.","journal-title":"Oncogene"},{"key":"2441_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/ncb2347","volume":"13","author":"J Mansfeld","year":"2011","unstructured":"Mansfeld J, Collin P, Collins MO, Choudhary JS, Pines J. APC15 drives the turnover of MCC-CDC20 to make the spindle assembly checkpoint responsive to kinetochore attachment. Nat Cell Biol. 2011;13:1234\u201343.","journal-title":"Nat Cell Biol"},{"key":"2441_CR15","doi-asserted-by":"publisher","first-page":"21561","DOI":"10.1074\/jbc.M112.364356","volume":"287","author":"HT Ma","year":"2012","unstructured":"Ma HT, Chan YY, Chen X, On KF, Poon RY. Depletion of p31comet protein promotes sensitivity to antimitotic drugs. J Biol Chem. 2012;287:21561\u20139.","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1038\/s41375-025-02811-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02441-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:41:13Z","timestamp":1762850473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02441-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2441"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02441-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The BV concentration units were incorrectly labeled as pM due to an error in molar conversion. The correct unit used in all experiments was nM. This labeling error appears in the following sections: Figures: 1D, 2A, 2B, 2C, 2F Supplementary Figures: 1A, 1D, 3B, 4G, 5B, 5C Supplementary Materials and Methods: Genome-wide CRISPR library screen The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02811-3","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02811-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MN received research funding from Takeda Pharmaceutical Company Limited. The other authors declare no competing financial interests related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}